$MKC

McCormick & Co. 3Q FY2026: Revenue $2024.8M, EPS $0.36— 10-Q Summary

McCormick & Co. reported 3Q FY2026 revenue of $2.02B, up 17.4% YoY, and diluted EPS of $0.36, down from $0.84 YoY. Growth was driven by the acquisition of McCormick de Mexico, while profitability was impacted by integration charges. Consumer volumes declined slightly, but Flavor Solutions saw gains. Gross margin improved despite inflationary pressures, supported by tariff refunds and cost savings.

Original reporting
Published Oct 1, 2026, 8:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
McCormick & Co. 3Q FY2026: Revenue $2024.8M, EPS $0.36— 10-Q Summary — source image
Decision brief

The 30-second read

$MKCBearishMed
01

Why it matters

The earnings miss may trigger a sell‑off, but revenue growth and margin improvement could support a rebound.

02

Market read

Mid‑cap consumer‑goods stock with immediate post‑earnings volatility.

03

What to watch

Strong revenue growth and improved gross margin may offset short‑term EPS pressure.

Relevance 8/10Novelty 8/10Timing: after-hours release on Oct 1, 2026

Background

McCormick & Co. reported its Q3 FY2026 results, noting a recent acquisition of a 75% stake in McCormick de Mexico and related integration costs.

Company-level read

Ticker impact

$MKCBearishHigh confidence
Context

Q3 FY2026 earnings released with revenue $2.02B and EPS $0.36, down YoY, highlighting integration charges from the McCormick de Mexico acquisition.

Expected impact

likely downside as market prices in lower profitability and integration expenses

Evidence & confidence

The report shows a 57% EPS decline and special charges, which typically trigger short-term selling pressure.

Market effects

Flavor and food ingredients sector may see broader scrutiny of integration risks after this miss.

U.S. consumer staples index could face slight drag pending market reaction.

Limited to investors tracking mid‑cap consumer‑goods stocks.

Counterpoint

Integration could unlock long‑term margin expansion, making the dip a buying opportunity.

Key entities

  • McCormick & Co.

    U.S. listed food‑flavoring company (ticker MKC).

Related articles

$ACNMed

Stocks making the biggest moves midday: Accenture, Synopsys, United Therapeutics, Vicor and more

Accenture rose 18% after Q4 revenue of $18.7B beat estimates. McCormick's Q3 results topped expectations but shares fell 2% amid Unilever's acquisition. McKesson gained 4% on reaffirmed guidance and a CVS Health partnership. United Therapeutics climbed 6% after a court ruling, while Liquidia dropped 15%. Constellation Energy gained 3% on a 20-year Amazon deal. Synopsys jumped 8% with 2027 revenue targets. Sigma Lithium slid 16% after halting production.

$MKCMed

McCormick Beat Estimates, But Shoppers Bought Less Spice

McCormick reported earnings beating estimates, driven by pricing and product mix, not increased sales volume. The company maintained its long-term outlook amid a challenging economic environment. The market is assessing risks related to its planned acquisition of Unilever's food business, expected to close by mid-2027. According to the report, McCormick's revenue increased by 2.2% due to price hikes.